Global Healthcare Quality Management Market Middle-East and Africa Of Middle East And Africa
| Label | Total | Australia | China | India | Japan | South Korea | Rest Of Asia Pacific |
|---|---|---|---|---|---|---|---|
| 2016 | 268.49 USD Mn | 20.17 USD Mn | 94.74 USD Mn | 50.75 USD Mn | 72.44 USD Mn | 16.13 USD Mn | 14.26 USD Mn |
| 2017 | 377.01 USD Mn | 28.38 USD Mn | 132.28 USD Mn | 71.63 USD Mn | 102.01 USD Mn | 22.67 USD Mn | 20.04 USD Mn |
| 2018 | 417.96 USD Mn | 31.53 USD Mn | 145.85 USD Mn | 79.81 USD Mn | 113.39 USD Mn | 25.16 USD Mn | 22.22 USD Mn |
| 2019 | 451.08 USD Mn | 33.62 USD Mn | 160.07 USD Mn | 85.96 USD Mn | 121.15 USD Mn | 26.77 USD Mn | 23.5 USD Mn |
| 2020 | 389.39 USD Mn | 28.67 USD Mn | 140.87 USD Mn | 73.98 USD Mn | 103.33 USD Mn | 22.69 USD Mn | 19.84 USD Mn |
| 2021 | 421.41 USD Mn | 30.53 USD Mn | 155.89 USD Mn | 79.75 USD Mn | 110.26 USD Mn | 24.07 USD Mn | 20.92 USD Mn |
| 2022 | 456.06 USD Mn | 32.45 USD Mn | 173.2 USD Mn | 85.61 USD Mn | 117.42 USD Mn | 25.42 USD Mn | 21.96 USD Mn |
| 2023 | 493.57 USD Mn | 34.42 USD Mn | 192.58 USD Mn | 91.73 USD Mn | 125.29 USD Mn | 26.74 USD Mn | 22.81 USD Mn |
| 2024 | 534.65 USD Mn | 36.61 USD Mn | 213.68 USD Mn | 98.57 USD Mn | 133.55 USD Mn | 28.27 USD Mn | 23.97 USD Mn |
| 2025 | 579.16 USD Mn | 38.87 USD Mn | 237.25 USD Mn | 105.7 USD Mn | 142.64 USD Mn | 29.77 USD Mn | 24.93 USD Mn |
| 2026 | 627.37 USD Mn | 41.34 USD Mn | 262.73 USD Mn | 113.59 USD Mn | 152.04 USD Mn | 31.47 USD Mn | 26.19 USD Mn |
| 2027 | 679.59 USD Mn | 43.89 USD Mn | 291.12 USD Mn | 121.81 USD Mn | 162.39 USD Mn | 33.14 USD Mn | 27.24 USD Mn |
Data Source: Wantstats Repository
Growth Outlook
- The Myasthenia Gravis Market Asia Pacific By Country market is on a steady long-term growth path. Segment value stands at roughly USD 627 Mn in 2026 and is projected to reach USD 680 Mn by 2027 — a gain of about 8% over the forecast period, translating to a CAGR in the high single digits.
- Acquired Myasthenia Gravis (MG) is a neuromuscular disease caused by autoantibodies against components of the neuromuscular junction. Patients suffer from fluctuating, fatigable muscle weakness that worsens with activity and improves with rest.
- What the regional split looks like (2026): China leads, holding roughly 42% of segment value — the single largest regional share. Japan is the second-largest contributor. India, Australia, South Korea and Rest Of Asia Pacific make up the remainder, in descending order.
- By 2027, China alone is expected to reach USD 291 Mn, with Japan at USD 162 Mn.
Market Dynamics
Acquired Myasthenia Gravis (MG) is a neuromuscular disease caused by autoantibodies against components of the neuromuscular junction.Patients suffer from fluctuating, fatigable muscle weakness that worsens with activity and improves with rest.
The global myasthenia gravis market is mainly driven by the rising research funding for myasthenia gravis, awareness programs and initiatives taken by associations, and the rising prevalence of MG. However, the high cost of treatment associated with MG may slow the growth of the market.
Unlock the Full Data
Get This Chart
Access the complete chart and underlying data to support your research, analysis, and business decisions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Get in Touch
Let's work together
support@wantstats.comSee our work in action
Start your data driven journey with us!
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Myasthenia Gravis Market Asia Pacific By Country



